Frequency of anticancer drug use at the end of life: a scoping review

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Szigethy, Endre
• dc.contributor.author Dorantes, Rosario
• dc.contributor.author Sugrañes Martínez, Miguel
• dc.contributor.author Madera, Meisser
• dc.contributor.author Solà Arnau, Ivan
• dc.contributor.author Urrútia, Gerard
• dc.contributor.author Bonfill, Xavier
• dc.date.accessioned 2024-02-28T08:03:14Z
• dc.date.available 2024-02-28T08:03:14Z
• dc.date.issued 2024
• dc.description.abstract Purpose: Anticancer drug use at the end of life places potential extra burdens on patients and the healthcare system. Previous articles show variability in methods and outcomes; thus, their results are not directly comparable. This scoping review describes the methods and extent of anticancer drug use at end of life. Methods: Systematic searches in Medline and Embase were conducted to identify articles reporting anticancer drug use at the end of life. Results: We selected 341 eligible publications, identifying key study features including timing of research, disease status, treatment schedule, treatment type, and treatment characteristics. Among the subset of 69 articles of all cancer types published within the last 5 years, we examined the frequency of anticancer drug use across various end of life periods. Conclusion: This comprehensive description of publications on anticancer drug use at end of life underscores the importance of methodological factors when designing studies and comparing outcomes.
• dc.format.mimetype application/pdf
• dc.identifier.citation Szigethy E, Dorantes R, Sugrañes M, Madera M, Sola I, Urrútia G, Bonfill X. Frequency of anticancer drug use at the end of life: a scoping review. Clin Transl Oncol. 2024 Jan;26(1):178-89. DOI: 10.1007/s12094-023-03234-1
• dc.identifier.doi http://dx.doi.org/10.1007/s12094-023-03234-1
• dc.identifier.issn 1699-048X
• dc.identifier.uri http://hdl.handle.net/10230/59275
• dc.language.iso eng
• dc.publisher Springer
• dc.relation.ispartof Clin Transl Oncol. 2024 Jan;26(1):178-89
• dc.rights © The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Anticancer agents
• dc.subject.keyword Medical overuse
• dc.subject.keyword Neoplasms
• dc.subject.keyword Terminal care
• dc.title Frequency of anticancer drug use at the end of life: a scoping review
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion